Figure 2

Tranilast attenuates the expression of mesenchymal markers in sNF96.2 cells. (a) Immunoblot analysis of fibronectin, collagen type I, N-cadherin, and α-tubulin (loading control) in sNF96.2 cells treated with the indicated concentrations of tranilast for 48 h. Blots are derived from different regions of the same gel. Uncropped images are shown in Supplementary Fig. S6. (b) Immunofluorescence analysis of collagen type III in sNF96.2 cells treated with tranilast (250 µM) or dimethyl sulfoxide (DMSO) vehicle for 48 h. Nuclei were stained with Hoechst 33342. Scale bar, 100 µm. (c) Quantification by ELISA of collagen type III in sNF96.2 cells incubated with or without tranilast (250 µM) for 48 h. Cell lysates were assayed. Data are means ± s.d. for duplicates from a representative experiment. *P < 0.05 versus control (Student’s unpaired t test). (d) Tumours formed by injected sNF96.2 cells in the brain of NOD/SCID recipient mice were subjected to histological analysis by Masson’s trichrome, Gitter, Elastica van Gieson, and Alcian blue staining.